No effect of dietary trans isomers of alpha-linolenic acid on platelet aggregation and haemostatic factors in european healthy men. The TRANSLinE study.
The aim of this study was to investigate the effect of trans alpha-linolenic acid on platelet aggregation and blood haemostasis. A randomized, double blind dietary intervention trial was carried out with healthy male volunteers (n=88) in three European centers. After a 6-week washout period where subjects avoided foods containing all trans fats, subjects either continued for 6 weeks with a low trans diet or a diet where trans alpha-linolenic acid provided 0.6% of energy (supplied as oil, margarine, cheese, muffins, and biscuits). At the end of the washout period the intake of trans polyunsaturated fats was 58+/-115 mg/day; this increased in patients on the high trans diet by +1344+/-328 mg/day, compared with +10+/-67 mg/day in patients on the low trans diet (p<0.01). The change in trans alpha-linolenic acid in plasma cholesteryl esters was 0.26+/-0. 20 on the high trans and 0.00+/-0.07% of fatty acids on the low trans diet (p<0.001). No effect of the high trans diet was observed on platelet aggregation: collagen EC(50) high trans 157+/-100, low trans 152+/-90 ng/mL (NS); U44619 EC(50) high trans 81+/-61, low trans 59+/-27 nM (NS). The high trans diet did not affect platelet thromboxane production, fibrinogen levels, factor VII, activated factor VIIa, or plasminogen activator inhibitor activity. There were no center-specific differences in response to the high trans diet. A relatively high amount of trans alpha-linolenic acid for 6 weeks does not increase the risk of coronary heart disease by promoting platelet aggregation and blood coagulation.
Armstrong
R A
RA
Centre for Food and Nutrition Research, Queen Margaret University College, Scotland, Edinburgh, United Kingdom. rarmstrong@qmuc.ac.uk
Chardigny
J M
JM
Beaufrère
B
B
Bretillon
L
L
Vermunt
S H
SH
Mensink
R P
RP
Macvean
A
A
Elton
R A
RA
Sébédio
J L
JL
Riemersma
R A
RA
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000737:chemistry; D002788:Cholesterol Esters / Q000097:blood; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005060:Europe / Q000453:epidemiology; D005167:Factor VII / Q000187:drug effects / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D005340:Fibrinogen / Q000187:drug effects / Q000378:metabolism; D006490:Hemostatics / Q000494:pharmacology*; D006801:Humans; D007536:Isomerism; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D010974:Platelet Aggregation / Q000187:drug effects*; D013929:Thromboxane B2 / Q000378:metabolism; D017962:alpha-Linolenic Acid / Q000494:pharmacology*
D002788:Cholesterol Esters; D005231:Fatty Acids, Unsaturated; D006490:Hemostatics; D017395:Plasminogen Activator Inhibitor 1; D017962:alpha-Linolenic Acid; D013929:Thromboxane B2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D005167:Factor VII; D005340:Fibrinogen; D003094:Collagen